Elevation Oncology, Inc.

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’

Merck & Co., Inc. has tweaked for the second time the lineup of antibody-drug conjugates (ADCs) it in-licensed from Chinese partner Kelun-Biotech in 2022, removing a Claudin 18.2-targeting ADC but ex

The pace of new financings seems to be picking up in 2024 after a decline in the fourth quarter of 2023 relative to the last quarter of 2022, but some drug developers still are struggling to raise new